Certain RA therapies are also known to increase the risk of VTE, including cyclooxygenase-2 inhibitors (2-fold increase in risk) [41] and glucocorticoids (2-3-fold increase in risk for short-term use) [42]. Here, PTGS2 is linked to rheumatoid arthritis.